Remicade is currently marketed for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.
Ranbaxy Laboratories today launched the first biosimilar version of Johnson and Johnson's Remicade, a drug used for treating various conditions including rheumatoid arthritis.
Infimab has been introduced in the Indian market through a licensing partnership with Epirus Biopharmaceuticals, Ranbaxy said in a statement. Infimab will be manufactured by Reliance Life Sciences at its facility in Mumbai, it added.
Remicade is currently marketed for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.
Also read: CCI asks Sun-Ranbaxy to divest some brands to avoid monopoly: Sources
"Infimab marks Ranbaxy's entry into mAb (Monoclonal Antibodies) biologics, and will help the company provide greater access to quality biologic medicines in management of conditions like rheumatoid arthritis," Ranbaxy said.
Ranbaxy Vice President & Country Head - India Region, Rajeev Sibal said: "Infimab offers a new opportunity in the management of conditions like rheumatoid arthritis. The product has been developed as per global standards and delivers a similar clinical outcome to the innovator. It will be available in India at a very significant discount as compared to the innovator drug."
Rheumatoid arthritis is one of the most common chronic inflammatory diseases causing disability.
Ranbaxy shares closed at Rs 616.90, up 0.73 per cent, on the BSE.
Ranbaxy Labs stock price
On December 01, 2014, Ranbaxy Laboratories closed at Rs 616.90, up Rs 4.50, or 0.73 percent. The 52-week high of the share was Rs 697.50 and the 52-week low was Rs 306.05.
The company's trailing 12-month (TTM) EPS was at Rs 20.91 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 29.5. The latest book value of the company is Rs 25.82 per share. At current value, the price-to-book value of the company is 23.89.
Anda sedang membaca artikel tentang
Ranbaxy launches arthritis drug Infimab in India
Dengan url
http://kebugaranhidup.blogspot.com/2014/12/ranbaxy-launches-arthritis-drug-infimab.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Ranbaxy launches arthritis drug Infimab in India
namun jangan lupa untuk meletakkan link
Ranbaxy launches arthritis drug Infimab in India
sebagai sumbernya
0 komentar:
Posting Komentar